Shih, Juliann http://orcid.org/0000-0002-4086-8651
Sarmashghi, Shahab
Zhakula-Kostadinova, Nadja http://orcid.org/0000-0001-7205-230X
Zhang, Shu
Georgis, Yohanna
Hoyt, Stephanie H. http://orcid.org/0000-0003-2570-6838
Cuoco, Michael S.
Gao, Galen F.
Spurr, Liam F.
Berger, Ashton C. http://orcid.org/0000-0001-5195-2528
Ha, Gavin http://orcid.org/0000-0001-7578-7272
Rendo, Veronica
Shen, Hui
Meyerson, Matthew http://orcid.org/0000-0002-9133-8108
Cherniack, Andrew D. http://orcid.org/0000-0003-0470-0111
Taylor, Alison M. http://orcid.org/0000-0001-9341-535X
Beroukhim, Rameen http://orcid.org/0000-0001-6303-3609
Article History
Received: 22 May 2021
Accepted: 26 May 2023
First Online: 28 June 2023
Competing interests
: G.F.G., A.C.B., A.D.C. and M.M. receive or received research support from Bayer AG. M.M. and A.M.T. received research support from Ono Pharmaceutical. M.M. is an equity holder of, consultant for, and Scientific Advisory Board chair for OrigiMed. M.M. additionally receives research support from Novo Nordisk and Janssen Pharmaceuticals, consults for Interline Therapeutics, and is an inventor of a patent for <i>EGFR</i> mutation diagnosis in lung cancer, licensed to Labcorp. R.B. consults for and owns equity in Scorpion Therapeutics and receives research support from Novartis. J.S., S.S., S.Z., N.Z.-K., Y.G., S.H.H., M.S.C., L.F.S., G.H., V.R. and H.S. declare no competing interests.